- 询价
- MedChemExpress(MCE)
- 美国
- HY-L088
- 2025年12月05日
企业认证
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
货期：询盘
- 供应商：
MedChemExpress LLC
- 规格：
询盘
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Angiogenesis-Related Compound Library
MCE 国际站：Angiogenesis-Related Compound Library
Angiogenesis is the physiological process through which new blood vessels are formed from pre-existing vessels. It occurs in various physiological processes e.g. embryonic development, menstrual cycle, exercise and wound healing etc. Angiogenesis is regulated by both endogenous activators and inhibitors. Some key activators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiogenin, TGF-β, etc. whereas angiogenesis inhibitors are angiostatin, endostatin, interferon, platelet factor 4, etc. The loss of balance between these opposing signals leads to life threatening diseases like cancer, cardiovascular and ischemic diseases etc. which are thus controlled by exogenous angiogenesis activators (for cardiovascular/ischemic disorders) and inhibitors (for cancer). MCE offers a unique collection of 1836 compounds with validated angiogenesis targets modulating properties. MCE angiogenesis-related compound library is an effective tool for angiogenesis research and discovery of angiogenesis-related drugs.
Description & Advantages:
• A unique collection of 1836 small molecule compounds with validated angiogenesis targets modulating properties.
• Targeting diverse targets, including VEGFR, Ephrin Receptor, PDGFR, FGFR, etc.
• A useful tool for the research of transcription factor-related regulation and diseases.
• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
• Structurally diverse, medicinally active, and cell permeable.
• Detailed compound information with structure, IC50, and brief introduction.
• Validated NMR and HPLC to ensure high purity and quality.
• All compounds are in stock and continuously updated.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验为什么要做血管生成实验？ 血管生长是肿瘤发生的关键步骤。无论原发性肿瘤还是继发性肿瘤，一旦生长直径超过1~2mm，都会有血管生成，这是由于肿瘤细胞自身可分泌多种生长因子，诱导血管生成。 由于肿瘤组织这种新生血管结构及功能异常，且血管基质不完善，这种 微血管容易发生渗漏，因此肿瘤细胞不需经过复杂的侵袭过程而直接穿透到血管内进入血流并在远隔部位形成转移。越来越多的研究表明，良性肿瘤血管生成稀少，血管生长缓慢；而大多数恶性肿瘤的血管生成密集且生长迅速，因此，血管生成在肿瘤的发展转移过程中起到重要作用
【求助】关于血管生成实验参与者：erik想设计一实验研究一蛋白对肿瘤细胞血管生成的影响，但不知道需要几种实验方法同时运用才能说明问题，或者说哪几种是常用的（最好简单易行），我是外行，谢谢指教！参与者：viv2005动脉环，小管生成，鸡胚，这几个比较常用，要么就是直接上动物参与者：erik我的意思是同时做哪几个就可以说明问题，呵呵，谢谢您的回复！参与者：viv2005我们都是一起做的，相互验证，至于做几个就有说服力了，这个没有统一的标准吧，你可以多看看外文文献都是怎么选择。
aoc_chen 大家好，现在打算用BD Growth Factor Reduced Matrigel来做体外血管生成实验，请问这个胶买回来需要稀释吗？文献只说了24孔板每孔加250ul胶，然后上面再铺人脐静脉内皮细胞，我不明白这250ul是稀释后的还是原液？若是稀释后的，是多大比例稀释！不甚感激！ ascorpio1 不需要稀释 aoc_chen 谢谢楼上兄弟！ roy
技术资料暂无技术资料 索取技术资料
